Lista de obras -

A Bayesian adaptive design for clinical trials in rare diseases

artículo científico publicado en 2016

A critical review of graphics for subgroup analyses in clinical trials

artículo científico publicado en 2020

A dose-finding design for dual-agent trials with patient-specific doses for one agent with application to an opiate detoxification trial

scientific article published on 10 December 2021

A false sense of security? Can tiered approach be trusted to accurately classify immunogenicity samples?

artículo científico publicado en 2016

A framework for prospectively defining progression rules for internal pilot studies monitoring recruitment

artículo científico publicado en 2017

A proposal for a new PhD level curriculum on quantitative methods for drug development.

artículo científico publicado en 2018

Adaptive clinical trials in tuberculosis: applications, challenges and solutions

artículo científico

Assessing goodness-of-fit for evaluation of dose-proportionality

artículo científico publicado en 2020

Assessing the feasibility of injectable growth-promoting therapy in Crohn's disease

artículo científico publicado en 2016

Asymmetric inner wedge group sequential tests with applications to verifying whether effective drug concentrations are similar in adults and children.

artículo científico publicado en 2016

Bayesian adaptive dose-escalation designs for simultaneously estimating the optimal and maximum safe dose based on safety and efficacy.

artículo científico publicado en 2017

Bayesian adaptive dose-escalation procedures for binary and continuous responses utilizing a gain function

artículo científico publicado en 2015

Bayesian sequential integration within a preclinical pharmacokinetic and pharmacodynamic modeling framework: Lessons learned

scientific article published on 01 April 2019

Designing and evaluating dose-escalation studies made easy: The MoDEsT web app

scientific article published on 19 December 2019

Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection

scientific article published on 12 October 2015

Endpoints for randomized controlled clinical trials for COVID-19 treatments

artículo científico publicado en 2020

Generalisations of a Bayesian decision-theoretic randomisation procedure and the impact of delayed responses

artículo científico publicado en 2022

Impact of an equality constraint on the class-specific residual variances in regression mixtures: A Monte Carlo simulation study

artículo científico publicado en 2015

Model selection based on combined penalties for biomarker identification

artículo científico publicado en 2017

Randomized dose-escalation designs for drug combination cancer trials with immunotherapy

artículo científico publicado en 2018

Recruitment progression rules for internal pilot studies monitoring recruitment.

artículo científico publicado en 2015

Response to comments on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat 17(5):593-606, Sep/Oct 2018., DOI: https://doi.org/10.1002/pst.1873

artículo científico publicado en 2019

Simultaneous confidence regions for multivariate bioequivalence

artículo científico

Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT

Understanding clinical prediction models as 'innovations': a mixed methods study in UK family practice

artículo científico publicado en 2016

Why are two mistakes not worse than one? A proposal for controlling the expected number of false claims

artículo científico publicado en 2016

Lista de obras de

A Bayesian adaptive design for clinical trials in rare diseases

A critical review of graphics for subgroup analyses in clinical trials

A dose-finding design for dual-agent trials with patient-specific doses for one agent with application to an opiate detoxification trial

A false sense of security? Can tiered approach be trusted to accurately classify immunogenicity samples?

A framework for prospectively defining progression rules for internal pilot studies monitoring recruitment

A proposal for a new PhD level curriculum on quantitative methods for drug development.

Adaptive clinical trials in tuberculosis: applications, challenges and solutions

Assessing goodness-of-fit for evaluation of dose-proportionality

Assessing the feasibility of injectable growth-promoting therapy in Crohn's disease

Asymmetric inner wedge group sequential tests with applications to verifying whether effective drug concentrations are similar in adults and children.

Bayesian adaptive dose-escalation designs for simultaneously estimating the optimal and maximum safe dose based on safety and efficacy.

Bayesian adaptive dose-escalation procedures for binary and continuous responses utilizing a gain function

Bayesian sequential integration within a preclinical pharmacokinetic and pharmacodynamic modeling framework: Lessons learned

Designing and evaluating dose-escalation studies made easy: The MoDEsT web app

Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection

Endpoints for randomized controlled clinical trials for COVID-19 treatments

Generalisations of a Bayesian decision-theoretic randomisation procedure and the impact of delayed responses

Impact of an equality constraint on the class-specific residual variances in regression mixtures: A Monte Carlo simulation study

Model selection based on combined penalties for biomarker identification

Randomized dose-escalation designs for drug combination cancer trials with immunotherapy

Recruitment progression rules for internal pilot studies monitoring recruitment.

Response to comments on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat 17(5):593-606, Sep/Oct 2018., DOI: https://doi.org/10.1002/pst.1873

Simultaneous confidence regions for multivariate bioequivalence

Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT

Understanding clinical prediction models as 'innovations': a mixed methods study in UK family practice

Why are two mistakes not worse than one? A proposal for controlling the expected number of false claims